In recent years, the success of prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals for the imaging and treatment of prostate cancer (PCa) patients has further enhanced this concept (Figure 1) thanks to the promising opportunities it offers [2]. This evidence concerns the gene FOLH1 and prostate cancer.